explore -WSS

explore

author：comprehensive 2025-09-30 12:10:52 - browse：5226

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The explosion of genetic testing requires a new approach

WSS

Impact of Dobbs ruling felt at reproductive medicine meeting

HHS leader on health, climate change and biopharma emissions

CEOs share strategies for surviving biotech slump

Moonlake's readout produced a cash windfall. Risks remain

The EU Joint Clinical Assessment needs to live up to its promise

United colonoscopy coverage change 'may cost lives,' doctors say

Wikipedia

explore

Bluebird and the case for gene therapy profits

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

In age of alternative facts, a scholarly course on calling out crap

Drug repurposing or repositioning? The language matters

STAT Summit: Biotech founders on deal

Affirmative action in medical school literally saved lives

Why health workers in Gaza are injured or die at high rates

Activists slam private health insurers over coverage restrictions

Why health workers in Gaza are injured or die at high rates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

United colonoscopy coverage change 'may cost lives,' doctors say

focus

Senate committee scrutinizes Medicare Advantage brokers

Hepatitis C has a cure — but many Americans still lack access to it

Studies point to risks of excluding people with obesity from drug trials

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: Michael J. Fox on progress in Parkinson's research

The cancer drug shortage isn’t new — and neither are the solutions

hotspot

hotspot

focus

knowledge